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Abstract 
Objective: Women treated for endometrial cancer commonly attend clinic-based follow-up for up to five years 
even though there is evidence of discrepancies on effectiveness of this approach to improve survival. 
Furthermore, recent guidelines recommend patient education be the cornerstone for follow-up practices rather 
than clinical investigations such as medical imaging and tumor markers as prompt and thorough investigations 
of symptoms are more likely to improve survival. This current practice is based on little evidence and thus 
alternative models need to be investigated. The overall aim of the study is to identify currently available symptom 
checklists, determine the comprehensiveness of identified checklists, and generate an updated list of symptoms 
potentially associated with a recurrence for future testing that will lead to early recurrence detection ultimately 
improving survival. This paper also explores the definition of recurrence, determines recurrence rates, and 
identifies post treatment surveillance schedules in reviewed studies.  
Methods/materials: We conducted a systematic review of the literature extracting; routine follow-up schedules; 
proportion of patients with symptomatic or asymptomatic recurrence; symptoms of recurrence; prevalence of 
these symptoms at recurrence.  
Results: Overall, three previous checklists, and 12 retrospective studies were identified meeting the selection 
criteria. The average rate of recurrence across the studies was 13% (range 3%-19%). The proportion of patients 
identified with a symptomatic recurrence varied widely (overall average 67%; range 41% to 91%). The most 
commonly reported symptoms were vaginal bleeding (25%), pain [not further described] (16%) and abdominal 
pain and/or discomfort and swelling (15%) which combined, represented 56% of the total reported symptoms. 
The three previous checklists listed 14 and this review identified an additional 24 symptoms (e.g. vaginal 
discharge, extremity/bone pain and constipation) not previously identified.  
Conclusion: The newly developed symptom checklist expands previous ones and will be used in a prospective 
study to assess sensitivity and specificity to identify recurrence compared to current standard follow-up 
examinations. Upon completion of successful testing in a prospective study, it could potentially provide an 
alternative form of follow-up to the traditional surveillance method to detect recurrences in endometrial cancer 
survivors.  
Keywords: Endometrial cancer; symptom checklist; recurrence; follow-up care; institutional follow-up 
protocol. 
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Introduction  
Endometrial cancer is the sixth most common cancer 
in women worldwide and is the fourteenth most 
common cancer overall with 320,000 new cases 
diagnosed in 2012 (1). A higher incidence of this 
cancer occurs in more developed countries with 
Northern America and Europe experiencing the 
highest incidence and Africa and Asia experiencing 
the lowest incidence (2) however in 2008, more than 
half of deaths (64%) were in developing countries (3). 
Survival varies widely depending on patients’ age, 
stage at diagnosis, grade and cell type (4) and appears 
to be poorer in developing countries (3). 
    There are various types of endometrial cancer, the 
most common being adenocarcinomas (cancers that 
begin in glandular cells) (5). Other types of 
endometrial cancers include adenosquamous 
carcinoma, serous carcinoma and clear cell 
carcinoma, which are typically more aggressive 
forms of cancer (5). Tests to detect endometrial 
cancers typically include physical examination, 
transvaginal ultrasound, hysteroscopy and biopsy, 
computerized tomography (CT), and magnetic 
resonance imaging (MRI) scans (6).  
    Primary treatment of endometrial cancer is 
surgical, and includes hysterectomy and bilateral 
salpingo-oophorectomy, with or without surgical 
staging. A small number of patients are considered at 
high risk of local, regional or distant relapse and will 
be recommended postoperative radiation, 
chemotherapy or a combination of both. Overall 13% 
of patients will develop recurrence (7) with the 
highest risk within the first three years after primary 
treatment (7-9). However cancer survival is lower in 
less developed countries due to a range of factors 
including lack of access to treatment (10), lack of 
resources (11) and economic disadvantage (12). 
    The majority of patients who develop recurrences 
present with symptoms (51%-100%) (9, 13-19) and 
only a minority are diagnosed during routine follow-
up visits (17-21). Furthermore, there are reports of 
routine follow-up leading to a delay in diagnosing 
recurrence as some patients wait until their next clinic 
visit to report symptoms (14, 18, 19, 22). Current 
follow-up regimes are largely based on individual 
hospitals’ protocols. According to some authors, this 
has not shown to improve survival and may be 
ineffective (13, 14, 16, 23-25).  
    Despite this lack of evidence, typically women are 
offered follow-up commonly consisting of physical 
examinations every three to four months for about 
two years, then extending to six monthly for the 
subsequent three years (13, 14, 26). Recently 
published guidelines suggest that patient education on 
symptoms, rather than investigations such as medical 
imaging and tumour markers should be the 
cornerstone for patients’ follow-up, as prompt and 
thorough investigation of symptoms is more likely to 
increase the chances of early detection of disease 
recurrence (27, 28).  
    To date, three symptom checklists have been 
developed for endometrial cancer, two for the purpose 
of educating patients about symptoms of recurrence, 
and the other for surveillance (28-30). However, the 
symptoms recorded in these checklists differ, and it is 
unknown how comprehensive these lists are.  
    The overall aim of this paper was to conduct, a 
systematic review of relevant contemporary literature 
to comprehensively generate an updated list of 
symptoms potentially associated with a recurrence of 
endometrial cancer. Literature searches undertaken 
suggests that controversies currently exist in regard to 
what constitutes effective surveillance management 
for endometrial cancer patients (22). This review 
explores alternative evidence based options to detect 
recurrences in women with endometrial cancer that 
will ultimately improve survival. Based on articles 
included in this review, this paper also explores the 
definition of endometrial cancer ‘recurrence’, 
determines recurrence rates in women with 
endometrial cancer, provides an overview of the 
leading symptoms of recurrence and identifies the 
post treatment surveillance schedules in these studies.  
Materials and methods  
Literature search strategy 
EBSCO host (Medline complete, CIHAHL full text, 
PsychINFO, Academic search elite), PubMed, Web 
of science and Google Scholar databases were 
searched. Based on information obtained from article 
abstracts, studies conducted on the adult population 
and published between 1982 and 2012 were retrieved. 
Key search terms used included “endometr*” “cancer 
or neoplasm,” or “carcinoma” “recurrence”, 
“relapse”, “signs,” “symptoms”, “surveillance” and 
use of MeSH terms “Endometrial 
neoplasms/diagnosis, rehabilitation, surgery, 
mortality, therapy, epidemiology, complications, 
nursing, prevention and control”. Reference lists of 
articles were searched and relevant articles retrieved. 
Case reports, letters, editorials and papers published 
in a language other than English were not considered 
for inclusion in this review. 
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Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram of 
article selection process  
 
Study selection criteria and data extracted 
All articles selected for inclusion in this review (Table 
1) reported on original data, were from patients who 
received successful curative treatment for 
endometrial cancer, and were disease-free prior to 
commencing follow-up. Studies needed to provide 
data on; duration, year of follow-up, stage using the 
International Federation of Gynecology and 
Obstetrics (FIGO) staging systems, routine 
investigations undertaken, recurrence rates including 
the proportion of symptomatic recurrences, leading 
symptoms of recurrence, and time frames of 
scheduled follow-up protocols. We extracted data on 
patients’ initial diagnosis (stage), the proportion of 
patients with symptomatic or asymptomatic 
recurrence, recurrence symptoms and prevalence, and 
routine follow-up schedules of institutions reported in 
studies. 
Extraction of data 
Data was extracted from each study. One study (26) 
focused on vaginal recurrences only, therefore was 
separated from other studies in Table 2, or excluded 
(Table 3) as it was not comparable to other studies 
which reported recurrences of all body sites. Another 
study was not included in Table 3 as it did not report 
details on symptoms of recurrences in the study 
population (28). In Table 3, several symptom 
categories from individual studies were combined 
into larger categories. For example, abdominal 
discomfort (one case), abdominal swelling (11 cases) 
Records identified through 
database searching 
(n = 14017) 
Additional records identified 
through article references sources  
(n = 16) 
Screened records excluded as studies not 
meeting inclusion criteria removed and 
duplicates removed  
(n = 10931) 
Abstracts of records 
screened 
(3102) 
Records excluded due to not 
meeting study criteria & 
duplicates removed  
(n =3022) 
Full-text articles assessed 
for eligibility  
(n = 80) 
Full-text articles excluded as 
did not report on symptoms of 
endometrial cancer and/or did 
not report on follow up 
protocol 
(n = 68) 
Studies included in 
quantitative analysis 
(n =12) and articles where 
symptoms check list 
identified (n=3) 
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and abdominal pain (84 cases) were combined into a 
larger category of abdominal 
pain/discomfort/swelling (see Table 3 footnote for 
other combined categories). 
    In the event where cases may belong to more than 
one category, cases were counted in all relevant 
categories. For example, the chest/chest wall pain 
category (14 cases) was derived from a combination 
of categories reported in individual studies as follows; 
‘pain in chest wall’ (7 cases) (19), ‘cough/chest wall 
pain’ (1 case) (14), and ‘dyspnoea, dry cough, chest 
pain’ (6 cases) (18). In the cough category, cases 
described above that were included in a combined 
category of cough and chest pain were counted in both 
categories under chest/chest wall pain and cough 
category (see Table 3 footnote). 
Statistical analysis 
Frequencies and proportions of recurrence presenting 
with or without symptoms were extracted. To 
estimate the proportion of patients experiencing a 
presenting symptom we used the formula x/y x 100 
where x = the number of patients reporting the 
symptom and y = the total population sample that 
experienced recurrence symptoms. When calculating 
decimal points for this study, figures were rounded up 
if ≥ 0.5, or rounded down if ≤ 0.4 to the nearest whole 
number. 
Results 
The initial search resulted in 14,017 potentially 
eligible abstracts. In the first screen, abstracts of 
articles were reviewed against study eligibility 
criteria. Articles not meeting the study criteria were 
excluded, as were duplicate studies. The second 
screen involved review of full text articles by two 
independent assessors of which again, duplicate 
articles and those not meeting study criteria were 
removed. As a result, 12 retrospective studies were 
identified (Figure 1). Summary of study 
characteristics are presented in Table 1. 
Definitions 
Five of the 12 studies used a consistent definition of 
recurrence (‘confirmed and documented disease 
following a minimum three month disease free 
interval from the time of primary treatment’) (14, 18, 
19, 22, 31, 32). Two studies required one month of 
being clinically disease free before being considered 
a recurrence (28), and one study defined recurrence as 
‘regrowth or reappearance of tumor in cases where no 
visible tumor was left at the completion of the 
operative procedure’ with no time interval specified 
(22). Some studies did not provide an overall 
recurrence definition (8, 13, 17, 21) but provided local 
(disease limited to the pelvic cavity or vagina), and 
distant recurrence definitions (any disease occurring 
outside of the pelvis (8). In contrast, Aalders and 
colleagues define local recurrence as ‘tumor regrowth 
anywhere in the pelvic structures or in the lymph 
nodes located below the pelvic brim’ (31). In this 
review, where no definition was provided for disease 
recurrence, we assumed the definition described by 
Podczaski applied (22), and where no definition for 
local or distant recurrence was provided, we assumed 
the definition described by Ueda applied (8), both as 
described above.  
    The definition of symptomatic and asymptomatic 
disease was consistent across articles (‘symptoms 
prior to clinical exams’ and ‘no complaints or 
symptoms but disease was detected by routine 
examinations’ respectively) (13, 17, 21, 22, 26, 28, 
31, 32). Four articles did not provide definitions, (8, 
14, 18, 19) for these we assumed the definition above 
applied.  
Recurrence rates 
Of the 12 studies reviewed, three (21, 28, 32) included 
patients with stage 1 and stage 1-2 disease only, four 
studies included patients with stages 1-3, (13, 17, 19, 
22) while five studies included all cancer stages (8, 
14, 18, 26, 31) (Table 2).  
    Overall, the average rate of recurrence was 13% 
(range 3%-19%). The recurrence rate was lower in 
studies that included stage 1 (7%) and stage 1-2 (8%) 
cases only, compared to studies that included 
participants with stage 3 (16%) or stage 4 disease 
(14%). The proportion of patients identified with 
symptomatic recurrence varied widely across the 
studies from 41% (28) to 91% (17). On average, 
symptomatic recurrence rates were lower in studies 
that included stage 1 participants only (58%) 
compared to studies that included stage 1-2 (81%), 
stage 1-3 (68%) or all stages (67%).  
Leading symptoms of recurrence 
Overall, 10 of the 12 studies described in detail 
symptoms that led to identification of recurrence 
(Table 3). The most commonly reported symptoms 
were vaginal bleeding (25%), pain [not further 
described] (16%), and abdominal pain and/or 
discomfort and swelling (15%). Combined, these 
three symptoms represented 56% of the total reported 
symptoms in this study. In contrast, a large number of 
symptoms such as, fever, cardiac arrhythmia, and 
hemianopsia were reported in less than 1% of 
recurrences. Symptoms grouped into ‘other’ category 
are included in Table 3 with the contents of the 
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Table 1. Summary characteristics of the 12 studies reviewed 
Author Year of 
treatment 
Duration of follow-
up of participants 
Routine investigations indicated by protocols 
Retrospective cohort studies: FIGO Stage I & II 
Morice et 
al. (2001) 
(32) 
1986-1995 Range: 12 to 137 
months 
(Median: 42 months) 
Gynaecological examination and pap smear every 3 months for 
the first year, 4 months during second year, 6 months during the 
third year and yearly thereafter. 
Chest X-ray and abdomino-pelviccultrasonography annually.  
Salani et al. 
(2011) (21) 
1997-2007 Range: 24 to 77 
months  
(Mean 46 months) 
Not indicated.  
*Reddoch 
et al. (1995) 
(28) 
1985-1992 (Median: 64 months) Physical examination and pap smear every 3 months for the first 
2 years, every 4 months for the third year, and every 6 months 
for the fourth and fifth years. 
A chest radiograph was ordered annually.  
Selected patients were also followed with tests of serial CA-125 
levels.  
Computed tomographic (CT) scans were ordered based on the 
patients’ complaints and physical findings. Many physicians also 
requested blood work, such as complete blood count and serum 
chemistries at follow-up visits.  
Retrospective cohort: All cancer stages (FIGO) 
Bristow et 
al. (2006) 
(26) 
1997-2005 Range: 3.4 to 143.9 
months 
(Median: 30 months) 
Pelvic examination and pap test every 3 months during the first 
year, 3 to 4 months during the second year and 6 monthly 
thereafter for total of 5 years. 
Chest radiograph and CT at the discretion of the treating 
physician, clinical risk factors and patient symptomatology.  
Ueda et al. 
(2010) (8) 
2000-2006 Range: 2 to 108 
months 
(Median: 43 months)  
Routine physical examinations, including a pelvic-rectal 
examination, vaginal vault cytology, and transvaginal 
ultrasonography (TV-USG), were performed at every visit.  
CT scan and chest X-ray performed biannually in the first year 
and annually thereafter. 
Tumor markers, including CA-125, one to four times annually in 
a subset of the cases.  
Ng et al. 
(1997) (14) 
1987-1994 Range: 3 to 90 
months  
(Median: 43 months)  
History. 
General examination. 
Cytological smear of the vault. 
Bimanual and recto-vaginal examination.  
Chest X-ray (not as routine).  
At every 1 to 2 months for first 2 years, every 3 months for the 
third year and every 6 months thereafter for 5 years.  
Agboola et 
al. (1997) 
(13) 
1982-1991 Range: 3 to 138 
months  
(Median: 55 months)  
Pelvic examination at each visit. 
Pap smear from the vaginal vault at each visit. 
Chest radiograph annually. 
Abdominal ultra sonograms, CT scans of the pelvis and abdomen 
and biopsies when clinically indicated.  
Shumsky et 
al. (1994) 
(18) 
1981-1986 Not stated  History at each visit.  
Cytology smears of vaginal vault at each visit. 
Bimanual and recto-vaginal examination at each visit.  
Chest X-ray biannually.  
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Podczaski 
et al. (1992) 
(22) 
1977-1987 (Median: 56 months)  Other examinations (not specified) every 3 months for 2 years, 
every 6 months for 3 years and yearly thereafter. 
Pap smear every 6 months.  
X-ray for first 5 years. 
Patients undergoing postoperative pelvic radiotherapy also 
underwent yearly intravenous pyelogram for 5 years after 
completion of treatment.  
Salvesen et 
al. (1997) 
(17) 
1981-1990 Range: 48 to 192 
months  
(Median: 108 
months) 
Gynaecological examination and Cytological smear every 3 
months for the first year, every 6 months in the second year then 
yearly for 8 years. 
Chest X-ray yearly with individually increasing intervals for 10 
years with routine attendance.  
Ultrasound investigation were perform when clinically indicated. 
Aalders et 
al. (1984) 
(31) 
1960-1976 Range: 36 to 228 
months 
Follow-up exams every 3 months during first year. 
Every 6 months during second year and annually thereafter.  
Case series 
Smith et al. 
(2007) (19) 
1990-2006 (Median: 109 
months)  
Clinical examinations every 3 months for 2 years. 
Vaginal vault smears performed twice a year for first 2 years. 
Clinical review is then extended to once every 6 months until 5 
years with vaginal vault cytology being performed once a year 
during this period.  
Additional investigations used intermittently within the follow-
up period included CT scans and serum CA-125 as clinically 
indicated.  
 
category varying between authors as noted in the 
footnote. 
Symptoms checklist 
Based on the reported symptoms of recurrences from 
these 12 studies listed in Table 3, a checklist was 
derived. This was compared to the three currently 
published symptom checklists (27, 28, 30). Table 4 
demonstrates this review found 14 symptoms that are 
common to all three checklists and additional 24 
symptoms of recurrence that were not previously 
identified. Examples of these additional symptoms 
include; vaginal discharge, extremity/bone pain and 
constipation.  
Study follow up schedules reported in articles 
Additionally, and in recognition of the ongoing 
debate on effectiveness of follow-up schedules, we 
also reviewed the reported post-treatment 
surveillance schedules of studies in this review which 
varied in the provision of details (Table 5).  
    In the first year, 75% of treatment centers provided 
one to three monthly surveillance. In the second year, 
33% offered three monthly follow-ups and another 
33% four monthly follow-ups (range one to six 
months) whereas in the third year, 50% of studies 
offered a six monthly follow-up schedule (three to 12 
months). 
Discussion 
Compared to previously published symptom 
checklists, this review identified 24 additional 
symptoms of recurrence that were not previously 
included, and confirmed the 14 symptoms that were 
common to all three checklists published earlier. Only 
five of these symptoms were identified in one or more 
of these symptom checklists. Some of these additional 
symptoms found in this paper occurred in small 
numbers when studies reviewed in this paper were 
combined; these symptoms include fever, cardiac 
arrhythmia and urethral lesion. Symptoms common to 
all checklists include; vaginal bleeding, abdominal 
pain/discomfort/swelling and cough, which were 
identified within the top four most commonly 
reported symptoms in this review. Pain [not further 
described] was the second most common symptom in 
this review. Although the three previous symptom 
checklists included back, hip and abdominal pain, it 
did not include neck, leg, bone, shoulder and chest 
Table 1. (Continued) 
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pain, which are examples of additional symptoms 
identified in this review. Some symptoms were 
reported in one of the three checklists only; such as 
neuropathy, lethargy, (30) dizziness and skin lesions 
(28). These variations in reported symptoms may be 
due to reasons, such as patients’ recall ability, health 
professionals’ acuity (prompting for symptoms), 
health service (time constraints at appointment), 
and/or clinical notes recording systems (automated 
drop down menus restricting options).  
    These findings are significant as previous studies 
have consistently demonstrated that the majority of 
endometrial cancer recurrences are symptomatic (7, 
9, 13-17, 19, 21, 25, 26, 28, 31, 32). This review 
applied stringent inclusion criteria and carefully 
dissected symptom reports across studies including 
women with differing stage of disease, and found an 
overall symptomatic recurrence rate of 67% which is 
within the 50% to 70% range reported in other studies 
(7, 27).  
In this study, on average, symptomatic recurrence 
rates were lower in studies that included stage 1 
participants only (58%) compared to studies that 
included stage 1-2 (81%), stage 1-3 (68%) or all 
stages (67%). Further studies need to be conducted to 
determine whether women with lower grades of 
endometrial cancer have less symptomatic 
recurrences compared to those with more advanced 
cancers. It may also suggest that women with lower 
grade cancers experience recurrence symptoms but 
these may not have significant impact on their 
life/lifestyle. For example, little/intermittent pain 
experienced and/or minor/ intermittent vaginal 
bleeding compared to symptomatic recurrences that 
occur in women with more advanced cancers, who 
may experience more severe pain and/or heavy 
vaginal bleeding. This may result in women with 
lower grade cancer under-reporting recurrence 
symptoms. However, as stated above, further 
investigation is required prior to reaching clear 
conclusions. 
 
Table 2. Endometrial cancer recurrence rates in the identified studies  
Sample/FIGO Total 
recurrences/sample 
(%) Recurrence 
identified by 
symptoms 
(%) 
Stage 1 only 
Salani et al. (21)  4/154 (3) 3/4 (75) 
Reddoch et al. (28)  39/398 (10) 14/39 (41) 
Average  (7)  (58) 
Stage 1 and 2 only 
Morice et al. (32) 27/351 (8) 22/27 (81) 
Stage 1-3 only 
Agboola et al. (13) 50/432 (12) 30/50 (60) 
^Smith et al. (19) 438/2637 (17) 199/280^ (71) 
Salvesen et al. (17) 47/249 (19) 43/47 (91) 
Podczaski et al. 
(22) 
47/300 (16) 23/47 (49) 
Average  (16)  (68) 
Stage 1-4 (all) 
Aalders et al. (31) 379/3393  (11) 258/379 (68) 
Ueda et al. (8) 29/271 (11) 13/29 (45) 
Ng et al. (14) 14/86 (16) 11/14 (79) 
Shumsky et al. (18) 53/317 (16) 40/53 (75) 
Average  (14)  (67) 
°Overall rate: 
Stage 1-4  
 (13)  (67) 
* Bristow et al. (26) 61/377 (16) 9/11* (82) 
^Detailed recurrence data were only available to analyse 280 patients 
° Not including study by Bristow 
*Study reported on vaginal recurrences only 
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Table 3. Symptoms of recurrence 
Symptoms tally of 10 studies reviewed1* 
Reported symptoms No of occurrences 
(combined) 
Total occurrences/total symptomatic 
reoccurrences of studies combined (%) (n=642) 
Vaginal bleeding˜ 158 25 
Pain 105 16 
Abdominal pain/discomfort/swelling˘ 96 15 
Cough˙ 46 7 
Hemoptysis (cough blood) 35 6 
Dyspnoea 32 5 
Self detected/palpable mass¨ 30 5 
Lethargy/weight loss° 24 4 
Lumbar/back pains 21 3 
Urinary frequency  18 3 
Pelvic pain 16 3 
Pedal edema 16 3 
Constipation 15 2 
Chest/chest wall pain 14 2 
Nausea 12 2 
Gastrointestinal pain, ascites  12 2 
Vaginal lesion 11 2 
Vomiting  11 2 
Pneumonia 11 1 
Leg swelling 10 1 
Diarrhea 9 1 
Vaginal discharge 9 <1 
DVT 8 <1 
Extremity/bone painˠ 5 <1 
Bowel/intestinal obstruction 4 <1 
Headaches 4 <1 
RUQ pain 3 <1 
Pain, malignant pericardial effusion omentum  2 <1 
Fever 1 <1 
Cardiac arrhythmia 1 <1 
Hemianopsia 1 <1 
Urethral lesion  1 <1 
Enlarged supraclavicular lymph node 1 <1 
Crural pains 1 <1 
Other# 76 12 
Other^ 54 8 
1 Some patients reported more than one symptom therefore total% exceeds 100% 
*Reddoch study (28) did not provide symptoms detail thus was excluded from this table 
* Bristow study (26) only reported on vaginal recurrences thus was excluded from this table 
˜ includes two cases reported as vaginal bleeding/discharge, and nine reported cases of vaginal discharge 
˘ once case abdominal discomfort, 11 cases abdominal swelling and 84 cases abdominal pain 
˙includes 11 cases of cough, dyspnoea, pain, pneumonia, one case of cough/chest pain, six cases of dyspnoea, dry cough and chest pain 
°lethargy and weight loss categories combined 
¨categories self detected mass, palpable mass and pelvic mass combined 
ˈcategories pain in chest wall, cough/chest wall pain, dyspnoea, dry cough, chest pain combined;  
ˠ includes one case of leg pain 
# Aalders study (31): edema, intestinal obstruction, anorexia, bone fracture, icterus and neurological symptoms 
^ Smith study (19): fall, haematuria, hemiparesis, pain neck, discharge umbilicus, pain hip, bloating, anaemia, pleural effusion, respiratory infection, 
bone pain, malena, mobility problems and shoulder pain
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    Given the high symptomatic recurrence rate, 
educating survivors on commonly occurring 
symptoms that may indicate recurrence such as 
vaginal bleeding, pain, abdominal 
discomfort/swelling is crucial and could complement 
surveillance care. It is recommended that health 
professionals use their discretion in determining 
appropriate symptom recurrence information to 
provide to individual cancer survivors, and remind 
patients to promptly seek professional advice if any 
symptoms are experienced or concerns arise.  
    A number of earlier reviews have suggested limited 
or no increased survival benefit of intensive hospital-
based follow-up surveillance for endometrial cancer 
survivors after receipt of primary treatment (7, 33). 
Furthermore, at least half of gynecologic oncology 
experts in a recent e-survey considered less intensive 
follow-up adequate for low-risk patients (6). Other 
surveillance suggestions include; tailoring follow-up 
care according to low and high risk groups (7, 18, 19, 
25, 32, 34), limiting the follow-up surveillance time 
period (13, 26) given that 80% of recurrences occur 
within the first three years of follow-up (25), or, 
abandoning routine follow-up schedules altogether 
(25). These results may suggest a readiness to explore 
alternate forms of surveillance for recurrence 
detection. In response to this, we have compiled an 
updated and expanded symptom checklist tool to aid 
clinicians and patients in the detection of symptoms 
of recurrence. This tool could be utilized in a variety 
of ways. For example, it could be used by specialist 
consultants, general practitioners and registered 
nurses as a prompt at appointments to encourage 
discussion of symptom experiences, used as an 
educational tool checklist to increase patient 
awareness of common recurrence symptoms (based 
on discretion of health professional), and may also be 
used in less traditional methods to follow-up, such as 
over the telephone to discuss symptoms and/or to 
provide patient education. This symptom checklist is 
currently being tested for sensitivity and is used to 
trial a novel and less-intensive approach of 
surveillance that could potentially be used as an 
alternative to traditional surveillance method to detect 
recurrences as early as possible in endometrial cancer 
survivors. 
    In breast cancer survivors, alternative follow-up 
regimes have already been tested systematically and 
in clinical trials. For example, the provision of follow-
up care by general practitioners rather than in-hospital 
specialists has been shown to be effective and 
acceptable to breast cancer patients (35). In a trial 
using telephone follow-up by specialist nurses after 
treatment for breast cancer, the telephone group were 
no more anxious as a result of foregoing clinic 
examinations and face-to-face consultations and 
reported higher levels of satisfaction than those 
attending traditional hospital clinics (36). The results 
of a systematic review of nurse-led versus 
conventional physician-led follow-up for cancer 
patients reported that patients appeared satisfied with 
nurse-led follow-up. Practical alternatives to 
conventional care included patient-initiated or 
telephone follow-up. While there were no statistically 
significant differences in survival, recurrence or 
psychological morbidity between the groups, further 
research is needed to determine suitability for 
gynecological cancer patients (37). In another study 
(n=36) which consisted of a clinical nurse specialist 
intervention among gynecological oncology patients, 
it was found that sexual functioning and quality of life 
were improved in the trial arm (38).  
    Current follow-up schedules (Table 5) commonly   
require survivors to attend about 14 hospital clinic 
visits within the first five years (39). In countries such 
as Australia, survivors often undertake extensive 
travel to the closest hospital for treatment. Survivors’ 
expectations of follow-up include the prevention of 
recurrence or diagnoses of recurrence as early as 
possible (40), whereas physicians’ mainly aim to see 
patients for on-going quality assurance and to 
diagnose complications as early as possible.  
Limitations  
This review relied on studies that had undertaken 
retrospective data collection or chart reviews, and the 
accuracy of data extracted from clinical records may 
vary (36). Other issues commonly relating to 
retrospective studies, such as missing data may have 
an unknown impact on the review. Additionally, 
reporting was often done in overlapping categories 
therefore a prospective study is needed to confirm that 
symptoms extracted here accurately reflect relevant 
symptoms. Variations of definitions of disease 
recurrence across the reviewed studies were also 
evident. Available data for detailed analysis were 
limited in some studies due to; a lack of details, no 
evidence of a disease-free period (19), reporting on 
vaginal recurrences only (26) and minimal 
information on follow-up schedules (30). 
    It is recommended that prospective cohort studies 
be conducted to determine alternative approaches of 
follow-up care for endometrial cancer patients. 
Randomized trials may be conducted to determine 
whether less intensive out of hospital follow up, or 
telephone care is equally effective compared to 
current standard care. The role of nurses in the 
provision of cancer follow-up care has been shown 
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Table 4: Comparison of previous symptom checklists to symptoms identified in this review 
Comprehensive symptom checklist 
proposed 
Previous symptom checklists 
*SGO (30) *NCCN (27) Reddoch et al. (28) 
Local 
Vaginal bleeding       
Vaginal discharge - - - 
Vaginal lesion - - - 
Urethral lesion - - - 
Urethral bleeding       
Frequent urination - - - 
Rectal bleeding/malena       
Rectal lesion - - - 
Pelvic pain       
Self detected/palpable pelvic mass - - - 
Hip pain       
Distant (extremities) 
Leg pain  - - - 
Bone/extremity pain - - - 
Shoulder pain - - - 
Swollen leg(s)       
Fracture - - - 
Distant (abdomen & back) 
Abdominal pain/discomfort       
Abdominal swelling/ascites        
Abdominal mass - - - 
Loss/decreased appetite -     
Nausea       
Vomiting        
Constipation - - - 
Diarrhoea - - - 
Back pain/lumber pain       
Distant (thoracic & upper body) 
Chest/right upper quadrant pain - - - 
Neck pain - - - 
Headache - - - 
Enlarged clavicular lymph node  - - - 
Cough        
Cardiac arrhythmia (irregular 
heartbeat) 
- - - 
Shortness of breath/dyspnoea       
Distant (systemic)  
Fever - - - 
Weight loss        
Lethargy/fatigue   - - 
Anaemia/looking pale - - - 
Dizziness/blackout - -   
Hemiparesis/muscle weakness - - - 
Neuropathy/numbers   - - 
Skin lesions - -   
Hemianopsia/blindness - - - 
Self detected mass - - - 
*SGO –Society of Gynaecologic Oncologist;  
*NCCN – National Comprehensive Cancer Network 
The symbols “” indicates symptom listed in the checklist and “-”denotes absence. 
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Table 5: Follow-up surveillance protocol of the 12 studies included in this review 
Post primary treatment follow up surveillance in the 12 identified studies 
Follow-up 
time 
Salani* 
(21) 
Reddoch 
(28) 
Morice  
(32) 
Agboola  
(13) 
Smith  
(19) 
 
 
Salvesen 
(41)  
Podczaski 
(22) 
Aalders  
(31) 
Ueda  
(8) 
Bristow  
(26) 
Ng  
(14) 
Shumsky 
(18) 
Year 1              
Monthly               
1-2 monthly              
3 monthly                       
3-4 monthly              
Year 2              
1-2 monthly               
3 monthly                 
3-4 monthly             
3-6 monthly               
4 monthly                 
6 monthly              
Year 3             
3 monthly               
3-6 monthly               
4 monthly               
6 monthly                   
6 monthly 
thereafter 
             
Annually               
Annually 
thereafter  
             
Year 4             
6 monthly                     
Annually               
Year 5             
6 monthly                      
Annually              
Annually 
thereafter 
             
Year 6              
6 monthly                 
Annually                
Annually 
thereafter  
              
Year 7             
6 monthly              
Annually                  
Year 8             
6 monthly               
Annually              
Annually 
thereafter 
             
Year 9             
Annually              
Year 10              
Annually              
*Salani study does not provide further breakdown of follow up schedules 
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to be valuable, cost-effective and acceptable in other 
cancer populations (42) thus, further research to 
determine suitability for endometrial cancer patients is 
recommended. Exploring patients’ and health 
professionals’ perspectives of follow-up care in the 
primary health care setting upon hospital discharge may 
also be of significant value to determine suitability and 
acceptability of this method for cancer patients.  
Conclusions 
The management of endometrial cancer follow-up 
remains controversial (22, 43, 44). There is an urgent 
need for a more efficient, effective and streamlined 
approach for endometrial cancer surveillance. Given 
that the majority of endometrial cancer recurrences 
present through symptoms, and recently published 
guidelines recommended patient education on 
symptoms be the cornerstone for patients’ follow-up for 
recurrence detection (27, 28), the use of a symptom 
checklist tool could prove to be successful as one 
modern alternative to follow-up care for endometrial 
cancer survivors upon completion of successful testing 
within a prospective study. 
    This review prepares the path to examine a novel and 
less-intensive approach of follow-up that could 
potentially replace the traditional methods, ultimately 
aiming to enhance survivorship outcomes, improve 
quality of life and reduce costs.  
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